COVID-19 Chapter 2: Disease - podcast episode cover

COVID-19 Chapter 2: Disease

Mar 23, 202048 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

This marks the second installment in our Anatomy of a Pandemic series, in which we discuss the various aspects of the COVID-19 pandemic. In this second chapter, we explore what we currently know about the disease itself, from symptom progression to incubation period and the role that asymptomatic individuals play in the transmission of disease. Our firsthand account, told from the perspective of a respiratory therapist, illustrates the severity of this disease and the frightening, yet very real, prospect of running out of medical equipment, protective gear, and hospital beds. We then discuss what we currently know about COVID-19 from a clinical disease perspective. We are joined by Dr. Colleen Kraft (interview recorded March 19, 2020), whose voice you may recognize from our first episode on coronaviruses. She helps to break down some of the disease-related questions sent in by our listeners. We wrap up the episode by discussing the top five things we learned from our expert. To help you get a better idea of the topics covered in this episode, we have listed the questions below:

  1. What does "respiratory droplet" transmission mean, and how is this different from something with "airborne" transmission? (15:08)
  2. What are the symptoms of COVID-19? (16:48)
  3. How long is the disease course, and how does this vary between mild vs severe symptoms? (18:45)
  4. What does "supportive care" mean in the context of caring for people who fall severely ill from COVID-19? (19:40)
  5. How much does viral load correlate with the severity of symptoms? (20:47)
  6. What is the incubation period of this disease, how long do people remain infectious, and are asymptomatic people contributing to the spread of disease? (22:22) 
  7. What are the groups that are particularly at risk for severe disease? (24:00)
  8. Why do children seem to be more resistant to this infection? What about children who are immunocompromised, are they at risk? (27:40)
  9. What is the case fatality rate, and how might we expect it to change throughout the course of this pandemic? (29:09)
  10. Are there long term complications associated with COVID-19? (31:58)
  11. Is it possible to get re-infected if you get this virus and then recover? (32:54)


The full article our firsthand account came from can be found here: https://www.propublica.org/article/a-medical-worker-describes--terrifying-lung-failure-from-covid19-even-in-his-young-patients

See omnystudio.com/listener for privacy information.

Transcript

Speaker 1

Reading about it in the news, I knew it was going to be bad, but we deal with the flu every year, so I was thinking, well, it's probably not that much worse than the flu. But seeing patients with COVID nineteen completely change my perspective and it's a lot more frightening. I have patients in their early forties, and yeah, I was kind of shocked. I'm seeing people who look relatively healthy with a minimal health history, and they're completely

wiped out, like they've been hit by a truck. This is knocking out what should be perfectly fit, healthy people. Patients will be on minimal support, on a little bit of oxygen, and then all of a sudden, they go into complete respiratory arrest, shut down and can't breathe at all. It's called acute respiratory distress syndrome ARDS. That means that the lungs are filled with fluid. Patients with ARDS are extremely difficult to oxygen eight. It has a really high

mortality rate, about forty percent. The way to manage it is to put a patient on a ventilator. The additional pressure helps the oxygen go into the bloodstream Normally. ARDS is something that happens over time as the lungs get more and more inflamed. But with this virus, it seems like it happens overnight. Typically with ards, the lungs become inflamed. It's like inflammation anywhere. If you have a burn on your arm, the skin around it turns red from additional

blood flow. The body is sending it additional nutrients to heal. The problem is when that happens in your lungs, fluid and extra blood starts going to the lungs. It first struck me how different it was when I saw my first coronavirus patient go bad. I was like, holy crap, this is not the flu. Watching this relatively young guy gasping for air, pink, frothy secretions coming out of his

tube and out of his mouth. The ventilator should have been doing the work of breathing, but he was still gasping for air, moving his mouth, moving his body, struggling.

When you're in that mindset of struggling to breathe and delirious with fever, you don't know when someone is trying to help you, so you'll try to rip the breathing tube out because you feel like it's choking you, but you're drowning when someone has an infection, I'm used to seeing the normal colors you associate with it, greens and yellows. The coronavirus. Patients with aards have been having a lot of secretions that are actually pink because they're filled with

blood cells that are leaking into their airways. They're essentially drowning in their own blood and fluids because their lungs are so full, so we're constantly having to suction out the secretions every time we go into their rooms. I worked a long stretch of days last week, and I watched it go from this novelty to a serious issue. We had one or two patients at our hospital, and then five to ten patients, and then twenty patients every day.

The intensity kept ratcheting up, more patients, and the patients themselves are starting to get sicker and sicker. When it first started, we all had tons of equipment, tons of supplies, and as we started getting more patients, we started to run out. They had to ration supplies. At first, we were trying to use one mask per patient. Then it was just you get one mask for positive patients, another mask for everyone else, and now it's just you get

one mask. Even if you survive AARDS. Although some damage can heal, it can also do long lasting damage to the lungs. They can get filled up with scar tissue. AARDS can lead to cognitive decline. Some people's muscles waste away and it takes them a long time to recover once they come off the ventilator. There is a very real possibility that we might run out of ICU beds, and at that point, I don't know what happens if patients get sick and need to be intubated and put

on a ventilator. Is that person going to die because we don't have the equipment to keep them alive?

Speaker 2

Oh my gosh.

Speaker 1

Yeah. That was an account from a respiratory therapist at a hospital in Louisiana who remained anonymous. For that account, I found it on Pro Publica. It was published on March twenty first, And we'll put a link to the full description in our show notes and on our website, because that was just a small excerpt from the description.

Speaker 2

It's you know, it's very eerie to read and to hear, because what it does is it reminds me of a lot of the first hand accounts from the nineteen eighteen Luenzo which I know has been brought up. The comparisons have been brought up constantly, and some are inappropriate comparisons. But just that description of healthy individuals being struck down, all people of all ages being struck down, and the horrible thought of not being able to breathe, Yeah, and drowning in your own fluids.

Speaker 1

Yeah, it's really scary.

Speaker 2

I mean, it is scary. And we should introduce ourselves before getting too much into this.

Speaker 3

Yeah, we should.

Speaker 2

Hi, I'm erin Welsh and I'm erin Oman Updyke and this is this podcast will kill you.

Speaker 1

Welcome back everyone, or maybe welcome for the first time if you jump part way into series. If you're one of those people. This is our not so many minisod series, Anatomy of a Pandemic, where we're answering all of your listeners submitted questions about COVID nineteen, the disease caused by SARS COVID two. In our first chapter, we covered the virus itself, so all of the biology of SARS CoV two.

In this episode, chapter two, we're going to talk about the disease that this virus causes, what it looks like, how it's spread, and how physicians and healthcare workers are dealing with this outbreak.

Speaker 2

But first, as always, it's quarantiny time.

Speaker 1

It's quarantine ay time.

Speaker 2

In this episode, we are drinking the creatively named quarantine y two, Quarantining number two. Aaron, what is in Quarantining number two?

Speaker 1

You know, Aaron, It's kind of a whiskey ginge.

Speaker 2

Yeah, I mean I would, I would call it a Kentucky mule perhaps if you happen to have a copper mug. I did not, so the picture is disappointingly non copper.

Speaker 1

It's all right, you did your best, thank you.

Speaker 4

Yeah.

Speaker 2

So it's basically ginger ale whisky of whatever kind of whiskey you want, and some lime.

Speaker 1

And we'll post the full recipe for that quarantine as well as our non alcoholic plusy Breta on our website and all of our social media channels as always as always.

Speaker 2

Okay, So, as we mentioned, we've talked about the virus itself, so now let's talk about the disease that this virus

is causing, COVID nineteen. And I do think that's a particularly important distinction because, as we'll hear more about this virus can infect you without necessarily causing severe disease, and that's super important in understanding the spread of the virus, because people who appear asymptomatic and otherwise healthy or just have very mild cases could still be infected with and therefore sneezing or coughing out the virus and spreading it

to other people. So we talked to doctor Colleenkraft, who many of you may recognize from our first coronavirus episode, and she's going to walk us through a lot of your questions about the clinical disease that this virus causes. Let's go over some of the basics first, so shall we?

Speaker 1

Let's we shall? So one big question is what is the timeline of this illness? And what you're going to see is that we still don't have the answers to every question when it comes to this disease, and the timeline is kind of one of those that we don't fully know, but we do have a better handle on it than we did in our episode that we released

back in February. So, first of all, it seems like the incubation period is on average about five days an incubation period is the time from when you're first exposed to that disease to when you first start showing symptoms of that disease. Okay, so on average this is about five days. It can range most studies, it seems like

the max range is about eleven. So when you hear about being quarantined for fourteen days, that's because we think and we're pretty sure that after fourteen days, if you haven't started to show symptoms, you're probably not going to show symptoms. So that's kind of the max range to make sure that you don't spread this disease unknowingly to someone else if you're exposed. And this number like around fourteen days, that's consistent with what we saw with SARS one, SARS classic.

Speaker 4

Okay.

Speaker 1

Now, the other thing is that from a retrospective study of people that had COVID, the severe disease. This study looked at people who were hospitalized for COVID, so pretty severely ill. The median time from when symptoms first started to discharge from the hospital was twenty two days. So that's a long time for somebody to be in the hospital. And I think that that's an important indication that for people who get seriously sick, they can be sick for

quite a long time. The other thing that this study looked at was viral shedding, so at least some measure of how long somebody might potentially be infectious, and they found that the median number of days that people were shedding virus was twenty days from the onset of symptoms, which is again a pretty long time if somebody is symptomatic, that is a long time yep, and longer than fourteen days.

Speaker 2

Yeah, that's I think. But I think the other thing that you mentioned that it's sort of this is just looking at people who had severe disease curR exactly, Yes, okay, So I wonder I think. I mean, of course, as this pandemic progresses, we're going to get more information about those people who have milder cases or are asymptomatic and how much virus they're shedding at various points throughout their course of infection.

Speaker 1

Exactly, Yeah, exactly. Okay, So then the question is what are some of these symptoms?

Speaker 2

Okay, So the biggest symptoms are the ones that most people have probably heard about in the news quite a lot, so fever, which, by the way, the death definition of a fever is a temperature of over one hundred point four degrees fahrenheit or thirty eight degrees celsius. Then there's also cough, generally a dry cough, not a super wet or a super productive cough, and then shortness of breath. So these are the general symptoms of the disease that we call COVID nineteen.

Speaker 4

But we know.

Speaker 2

Now that SARS covy two, the virus like SARS one and MERS, can infect your lung tissue and cause a lower respiratory disease, not only an upper respiratory infection the way most of the common coronaviruses do. Okay, So what does that mean, Well, it means the possibility of very severe disease like we heard about in the first hand account, and in the case of this virus, it seems that

about twenty percent of cases are severe. And that doesn't mean that twenty percent of cases need ICEE you and ventilator care, but it does mean that potentially up to twenty percent of cases may need at least hospitalization and

some oxygen support or some IV fluid support. An analysis from China suggest that there at least about fourteen percent of cases were severe and five percent were critical, And that means the same kind of picture that we talked about in our coronavirus episode when we talked about SARS, and the same description you heard in the first hand account so ards, ground glass opacities on X rays, potentially

needing intubation. It's serious. It's a serious, serious disease, and people can also go into shock, which we've talked about a lot on the podcast. But essentially what that means is that your organs aren't getting enough blood flow in this case because of overwhelming infection, which leads to leakage of fluids and then hypoperfusion, and then of course there is also always the risk of a secondary infection on top of this viral infection.

Speaker 1

It can be pretty gnarly. But also in this case, what we see that is different from SARS and mers and what in our first episode about coronaviruses was still kind of a gray zone. That's a lot more clear now is that asymptomatic or very mildly symptomatic infection is not only possible, but it's likely actually responsible for quite

a lot of the spread of this disease. It's estimated that about eighty percent of cases are mild, which, while that's great news for the majority of people who get infected, it means you're not necessarily going to be looking at such a severe disease. It also means that this disease is easier to spread since not everyone who's sick maybe even realizes that they're sick. And how does this disease spread.

Speaker 2

Erin well, respiratory droplets as we well know, but we're not going to go into that. We're going to allow our expert, doctor Collingcraft from Emory University to explain how respiratory droplets work, as well as other characteristics of this disease, how wo'ds spread, how we're testing for it, who we're testing for it, and finally, how we treat it.

Speaker 1

Right after this break, my.

Speaker 4

Name is Colleen Kraft and I'm the Associate chief Medical Officer at Emory University Hospital. My training is in infectious diseases and clinical microbiology.

Speaker 2

Thank you again, so so much for joining us. We know that you have just been swamped with work and so we really appreciate you taking the time to kind of talk about COVID nineteen. I mean since our first interview with you, which has been you know, about a month and a half ago. A lot has happened.

Speaker 4

Yes, like a lifetime has happened. That's how I feel.

Speaker 1

Yeah, yeah, so we'll jump right in. We are talking today, of course, about SARS COVID two, the virus that causes COVID nineteen. So we know that it's transmitted through respiratory droplets or direct contact with somebody's respiratory droplets, like other coronaviruses. Can you tell us a little bit about what that means in contrast to viruses that are airborne and when people talk about respiratory droplets, like what exactly does that include?

Speaker 4

Sure? So I think it's it was really funny to hear. I've been to a number of town halls around Emory and I had one of my audience members best described it as, you know, it's your saliva, So it's sort of I view respiratory droplets as being sort of the wet aspects of our coughs and sneeze, and that's that. I thought that was very well described that way by this employee. And I didn't answer your your airborne question.

So what happens is when we cough or sneeze, it's those, it's like a wet, heavy droplet, and that kind of goes to the ground right sooner because it's heavy. But when they are really small, then they can aerosolize and they can actually sort of hang around in the air for longer. And so that's why every time there's a new respiratory virus we sort of pretend like it's airborne, just to make sure it's not airborne, because that is sort of a different transmission route that that can hang

in the air longer and it can go farther. But you know, from what everything we know, this coronavirus still behaves like our droplet spread coronaviruses, gotcha.

Speaker 2

So at this point we have a better idea of what a typical course of COVID nineteen looks like. Can you walk us through what that is like? You know, day one, day two, what do you typically see?

Speaker 4

Yeah, so we're seeing the same things as being seen and observed in other parts of the world. And so we have the vast majority of these individuals have a cold. It may be an unpleasant cold more than for others, but most people have a very mild illness, probably most similar to our common cold. In general. We are seeing people though, that come in with basically a viral pneumonia type picture. Viral pneumonia should really make the hairs on the back of your neck stand up, because that's probably

what happened in the nineteen eighteen Spanish flu. And this is again along with the airborne aspect, this is what we're always looking for in these new viruses. Does it have a propensity to cause lower respiratory tract infection? If it does, that makes us scared because we can't. While we can do a lot with bacterial pneumonia, a viral pneumonia is very scary because usually don't we can't treat most of the viruses that we get, and so we definitely don't it down and the lung where it can

cause scarring and difficulty breathing. And so for a subset of people that for the most part tend to be ill ill at baseline, we have a group of people that also are getting symptomatic lower respiratory tracts syndrome who are not quite as ill as the typical person we're

hearing about that is succumbing to this disease. So we've had a number of individuals that yes, they have other medical problems, but they don't necessarily have respiratory medical problems, and they are having you know, sort of a viral pneumonia picture, and we have had a few that have been needed to have mechanical ventilation or a breathing tube.

Speaker 2

Gotcha about how long does is the course of disease? You know, I know that for some people who have milder cases it may be shorter than for others. But what do we see on average or what does it look like for the people with more mild symptoms compared to the people with more severe outcomes.

Speaker 4

I would say it's it's that typical three day kind of feeling bad, achy, and then the next day is maybe a little bit better, not great, and then the next day you're sort of back to feeling like you're among the living. And then you know, then we also recommend for at least for our employees to sort of, you know, kind of self isolate for a few more days, just to make sure you're not sort of still having those secretions coffin sneeze because we don't want to keep

spreading it. And so that's sort of a mild course. The more severe courses tend to be you know, I think the damage is done within the first week, and then what we're doing is trying to support the body so the body can mend after that.

Speaker 2

What does that supportive care look like, both in terms of that during that first week of intense symptoms and then the sort of you know, the healing stage.

Speaker 4

Right, So it sounds like it's your grandmother patting your hand, is what supportive care sounds like, I think to most people. But in the case of some individuals that have severe disease, it may mean that they have a breathing tube, they're in an ICU, they have many other things that are helping support their body until the body can kind of

get rid of the virus itself. So this is sort of how we describe things back in the bola days, where you know, most of the time what we're doing is just supporting, like with life support, basically to try to keep things going until the body can create and clear that virus. That's what happened during a bola with coronavirus. It's sort of similar. So supportive care when you're at home maybe niquil and television, which sounds really great to me right now, and when you're in the hospital. Though.

What that is is if we need to help one of your body systems function, we will do that.

Speaker 1

Okay, do we know at this point how much things like viral load might correlate with the severity of symptoms? Are the people that have milder cases, are they as infectious to others? Are they shedding as much viral particles as these more severe cases?

Speaker 4

Right? So, I think this is a great question. And I think as this is where you're going to see, my laboratory in side come out quite a bit. So it's really easy when we talk about viral load in the blood or plasma or serum to sort of understand how to standardize that by copies per mili liter or something like that. When we're doing a respiratory swab. I

think it's really hard to standardize. And because this test is so new, we don't have the test standardize in and of itself, So the testing results at our institution may be a little bit variable compared to another institution, and that's because we don't have a gold standard yet to compare on all of the machines. So I agree

with you. However, we have seen very anecdotally that we've had people with very high viral loads that basically didn't even look like they were sick, and we question whether or not we should even swab them. And I had extremely high amounts in their nose, whereas we've also had people that have had moderate amounts that are sick and

on a ventilator. And so, while I think there's an aspect that correlates, I think the way that we obtained the swab is going to make this difficult unless there's some sort of serum or plasma or surrogate tests we can use that can be very standardized with its input.

Speaker 2

And so going revisiting this aspect of perhaps asymptomatic individuals or people with very very mild cases of this, can you talk about sort of the incubation period when people might start becoming infectious, how long they remain infectious, and then sort of how much do you think asymptomatic individuals might be contributing to the spread of disease.

Speaker 4

So I think they probably are contributing to the spread of disease. I think that's why some of these more dramatic things that we're seeing are the social distancing and being really aware of your even more so just your own hand hygiene, just your own persona as it relates to anybody else. And so I think that we are taking measures to have that not happen. Right school's closing. Let's talk about where there could be a lot of

asymptomatic spread of disease. That would be a school. So you got a bunch of kids shedding virus everywhere in close proximity, with limited hand and face and everything hygiene, And you can tell I have children, and that's just like, that's just a setup for transmission. So I do think that while asymptomatic people are shedding, we're really taking dramatic efforts on like I've ever seen in my short lifetime.

I suppose really to even work on stopping that. I mean, hospitals aren't allowing very many visitors, you know, public places of all but canceled everything. So we're actually really trying to break that cycle, which I think has to me never been really done to this extreme. Yeah.

Speaker 1

Yeah, And you mentioned as well that it seems at this point pretty well established that it's older people and people with other underlying health conditions or people that are otherwise immunal compromise that are more likely to experience this severe disease. But we've gotten a lot of people asking us for a bit more clarity about these groups, like what age is it that people are considered elderly or at risk? And is it any sort of immune compromise

that makes you more vulnerable? Or what are these pre existing health conditions that we're most concerned with in terms of the higher risk categories for this disease.

Speaker 4

Right, So, I think the way to do that, and the way I've been gut checking a number of these questions that we really just don't know yet because we don't know everything about this virus, is to think about influenza and sort of start there. Right, So, in older adults, influenza tends to be more severe because it's sort of

tipping off chronic conditions that get worse. So if you have bad heart disease and you get a respiratory virus infection, sometimes people even have heart attacks from viruses, which is very rare, but we think probably happens more than we understand, but it may basically, you know, they may be in sort of a tenuous balance, like everything's kind of holding together, but it's it's it doesn't take much to push over

into feeling a lot worse. And so I just think about the people that are at risk for our typical seasonal influencer are going to be the same people they are at risk, So anybody that has lung problems, anybody who's immune system can't fight it off. I think it's hard to say to actual groups, and you know, we're seeing that many older people are being spared and and some younger people that are younger than we thought are

getting it. So it's really I think we're you know, we're trying to define the syndrome, as we're trying to diagnose cases, as we're trying to bring up testing, and so I think, you know, we will by the end of this outbreak have more resolution on what that looks like. But I think right now, you know, and it's probably at this point near seasonal influenza, gotcha.

Speaker 2

There were two groups specifically that we got a lot of emails about and questions about, and one of those groups was people with diabetes type one, and they were wondering, you know, people, I keep seeing that people with diabetes are more at risk, does that include me? And then the other group that we got a lot of questions from were people who were pregnant or people with newborns.

Speaker 4

Right, So the pregnancy thing, I think is always a we always are concerned about it very highly. I don't think that there's been any data that actually shows there's poorer outcomes. I know that doctor Denise Jamison from Emory has published a little bit about this, at least what's known from stars and mers, And while early trimester is always concerning for anything, there's no evidence that anybody again

has had any pregnancy complications from this. However, in general we don't like to test that theory, and so we tend to be protective around pregnant women for sure. In terms of those with diabetes, I think it's it's again not quite known what the aspects of diabetes, except that there's some level of sluggish immune and response. I wouldn't say immune compromise entirely. I think it depends on how well your blood sugars are controlled, how many complications you

already have from diabetes. Do you have type one diabetes, which can tend to be much more severe than type two diabetes. I think some of those questions, you know, may be elucidated as things progress.

Speaker 2

Gotcha, so you know on these in this discussion of high risk groups and low risk groups or varying risk in general. One of the things that we've seen is that children seem to experience a milder disease than some of the other age groups. Do we know why that is? Our immuno compromised kids just asvulnerable as immunocompromise people of other ages.

Speaker 4

I should have read my pediatric textbook a little bit more, But there are definitely a number of viruses that are much worse than adults than kids. And then we sort of have vice versa where kids tend to have maybe an increased predilection, or maybe it's just because by the time you're an adult that you're immune to it, and when you're a kid you're sort of seeing it for the first time. So there is always this dichotomy of

is it worse in kids are better in kids? This scenario really seems to be that the kids are these asymptomatic probably shedds, right, But we already discussed a little bit earlier, and so this virus just for whatever reason, is not that severe in children. But again, it may

be that most coronaviruses aren't. We just haven't studied them because we kind of haven't cared because they haven't done that severe in adults, and in terms of immunocompromised kids, I suppose that they are more at risk, but I suppose that they may also become increased vectors. They may just shed longer. But again, I'm not a pediatrician, so I hesitate to sort of fully answer that one with confidence.

Speaker 3

Yeah, that makes sense.

Speaker 1

So can you explain a little bit about how we are getting the numbers for things like the case fatality rate right now? Is that something that is still a moving target? Do you think that we might be able to see that number decrease as more asymptomatic or mild cases are identified, since at this point it seems like testing is mostly focused on the severe cases exactly.

Speaker 4

Yeah, so I think this is you know where again my laboratory and background and the logic of this is really interesting in a is it interesting as anything can get right now? So what really I think is interesting is we really do have a decrease in throughput ability right now with our diagnostic testing. That's because we're building the car as we drive it, right So, there's been

all this contrived controversy about test kit shortage. Well, we just discovered this virus and we just made a test for it, and when we make tests that are new, we have to go back to old school methods, which are a bit slow, and so I think I don't know what expectation we had that we had to have like a rapid test the next day. I think it

was a little bit. I don't know who's stettying that standard, but the standard is unattainable, and so I think that by virtue of the fact that we're going to start testing more and more people over the next month, we are going to see that that denominator is going to stretch out. So we're going to have people that are asymptomatic, barely symptomatic that are going to be positive, and that will make that case fatality rate drop. I think it can look higher. Again, it's exactly what you said. It's

selection bias. So when you're only testing the sickest of the sick, then you're only going to find a high case fatality rate. I personally am the current gatekeeper to who gets on our daily test in house that we've developed, and we only have room as of today. This probably is actually going to change tomorrow. So you know, I have to gatekeep and prioritize who gets on our in house run which takes twenty four hours versus send out to a referral lab, which may take seven days. Well,

who do I prioritize? I mean, who would you guys prioritize? So we're going to do impatients because we're also using a lot of personal protective equipment to care for these individuals, and so we want to be able to take them out of that if they don't need it, and then we can keep our supplied. You know, we need less

supplies if we do it that way. And then we're also tests prioritizing our workforce, right, so we want to make sure that the physical therapists and the respiratory therapists and the you know, tech and everybody can come back to work because we want to make sure we can keep taking care of these sick patients when they come in. Mm hm hm.

Speaker 1

That makes sense.

Speaker 2

So I know that it's early stages yet again in this pandemic, but do what do we know so far about longer term health consequences for people who have gotten sick, maybe have gotten mild or severe in particular, disease, and are there long term health consequences they have, like lung damage or other issues.

Speaker 4

So the logic that I use is that anything that damages the lung can cause long term consequences. So the lung only knows how to do one thing when it's damaged, and that's to scar down. And so that's why our bodies have this lovely cough reflex so that all that stuff doesn't go into our lungs and cost scarring and damage. So when we have a virus that's infecting our lung cells, then that's going to cause this scarring to happen, and

we potentially could see long term damage. But that's the same as sort of anything that comes and damages the lung.

Speaker 1

Okay, So another question that a lot of people had, and I know we probably don't fully know the end answer to this, but maybe we can sort of estimate based on what we know so far about coronaviruses in general or from you know, the previous outbreaks. Is do we know about whether it seems possible to become reinfected with this virus if you get it and then recover from that infection.

Speaker 4

Yeah, So I was just on another alumni call today and have this very same question. We probably get this question every day, and so in general we probably don't know for sure. I think because this is a novel coronavirus introduced to the population, we will likely understand more because there's more attention to it. My understanding is that when we have viral infections, we do become immune to them, but remember that it depends on how systemically ill we

are as well. So you know, it's a complicated immunology at this at our nasal source. Right. We talked already about how trying to say the viral load from the nose is not a very consistently sampled area, and so I think in the same way that immunology may be difficult to totally separate out because there may be an aspect of our mucosal immunology that plays a large role in whether or not that virus comes back to us. Right, So we may have just symptomatically gotten through it, but

did we actually form true defense against it? And again, I think, you know I would. I don't pretend to know that much about immunology except the big picture stuff. So I hope that was helpful.

Speaker 2

Yeah, absolutely so. In our first episode on coronaviruses, we ended it by asking you, what about this disease concerns you and what about it you know, makes you say hold off on the panic or maybe as reason for optimism. Has your answer changed at all since that time?

Speaker 4

My answer has changed, Dear Errands. I think that we do see that it causes laura respiratory tract infection, much like other viruses that we know, such as influenza, and so I am happy to say that it's not as severe as stars or mers, but it's not insignificant, and we are seeing a lot of individuals you know, in the hospital that have this. I think my optimism is

that I'm trying to be optimistic every day. The supply chain issues and the personal finance issues and the childcare issues, to me, are making this very personally difficult for a lot of people. It's one thing to sort of have a bad blue season and us to have sort of sicker patients or more patients, but the personal protective equipment and you know, no visitors to the hospital, all those

things really are stressing people personally. And so I'm just trying to be optimistic that a lot of this social isolation that we have implemented will act actually make a difference, because you know, we're sort of, at least in Georgia, we're sort of coming into the surge part of it for our location, and I think everybody's going to go through that and you know, have to just come out

on the other side. But there's a lot of things that you know, when I was bubbly three weeks ago or whenever that was, I could not have imagined the stress of like not having swabs to test, or you know, I could have understood and foreseen not having enough tests or having a low throughput on test. That's something we deal with with other scenarios that's not that uncommon. But I think the financial personal tolls that are occurring in the midst of trying this being very busy, like during

a respiratory season, it's been a lot more difficult. So I'm just hoping that our interventions, while initially seeing meing very dramatic, will actually sort of alleviate the stress.

Speaker 2

That was fantastic. Thank you so much doctor Kraft for joining us and taking time out of your ridiculously busy schedule. We really appreciate it.

Speaker 1

We can't believe that you made time for us. We really really appreciate it.

Speaker 2

Yeah, we do, all right. So things we learned. Number one, one of the big gray areas that we didn't fully know the answer to in our first coronavirus episode back in February was whether or not people were infectious before they were symptomatic, and whether there was asymptomatic spread or

even super mild infections contributing to the transmission. So in this interview, we learned that although we don't know exactly how much virus people might be shedding throughout their infection, that there are asymptomatic or very mildly symptomatic individuals and that they're contributing to the spread. That is super clear.

At this point, Doctor Kraft mentioned testing someone who seemed perfectly healthy and finding a ton of virus in comparison to someone else who was more severely ill and had a lot less virus in their sample. And there are some difficulties with this in terms of standardizing the test and whether that person who had less virus did actually

have less virus. We don't know much about the viral load changes throughout the infection, but this I still think personally is alarming or at least is going to make

transmission of this disease much more difficult to stop. Absolutely, And there was actually a nice modeling study that used data from Muhan and fits some mathematical models to the actual infection data, and it suggested that up to like eighty six percent, eighty six percent of the spread of infection was likely due to unidentified cases.

Speaker 1

That's a lot.

Speaker 2

It's a lot, And it makes sense that this is possible if we know that asymptomatic or mild infections are possible and common.

Speaker 1

Absolutely. Number two. Another big thing I think to take away from what we talked about with doctor Craft and what we heard in the first hand account is that in people who get severely ill from this disease, these people really need to be hospitalized. And that's what's really

scary about this and why you hear a lot. And we'll talk more in the future about why we're trying so hard to flatten this curve, because if our hospitals get overrun, then more people could die simply because there aren't enough beds, or there aren't enough staff, or there isn't enough equipment to actually care for them. So for people that need to be hospitalized for supportive care, like

doctor Craft was talking about. But that means that these people aren't able to breathe well enough on their own, so they either need a tube down their throat and to be on a respirator, or even if they don't need that maximal support, they still need supplemental oxygen or a positive pressure face mask. All of these things you can only get in the hospital. And the other thing is that even if people don't need help breathing, they

might end up needing ivy fluid support as well. When you get sick, when you're not eating, not drinking normally, and you're spiking high fevers, your body is working really hard to fight off an infection and you can end up severely dehydrated pretty quickly. So for some people, if they get very sick, just drinking fluids isn't going to be enough to repleate that volume. So another way that we see supportive care in the hospital is support from

ivy fluids as well. And all of these are support measures just to help your body get through this process, not even addressing the virus itself. And we'll talk in a future episode about what's being done on those types of treatments, but I think understanding that people who get severely ill really need the resources that are available in hospitals is an important aspect.

Speaker 2

Of this disease absolutely. Number three. So looking at these different risk groups, I think there are a couple of important things to keep in mind. One is that we don't fully know the risks across different groups, and part of that is because this is so new and we don't have a ton of data. And another part is that because, like doctor Rasmussen said in our episode about the virus biology, there's a lot of variation in host

response that we can't always predict. On top of that, we have these, as we mentioned, a bunch of these asymptomatic or very mildly symptomatic individuals that are contributing to the spread of this virus. That means that we all kind of have to assume that we are potentially infectious at any point, because it's our job to help protect

those around us that might be more vulnerable. And another thing I want to point out is that in the US so far, like thirty eight percent of people that are hospitalized with COVID nineteen right now are under fifty five.

Speaker 1

That's a lot of young people.

Speaker 2

It's a lot. It's a lot, And I think that's not necessarily been what the messaging has suggested in terms of, oh, if you're not old, if you don't have underlying health conditions, then you're safe. Which, first of all, that's kind of mean to the people who are older and who do have these underlying health conditions that you're like, oh, well, you know, go ahead and die, I'm going to be fine, right, Like.

Speaker 1

These are still human beings we're talking about.

Speaker 2

Here, human beings. Yeah, And so I think that that messaging that everyone is susceptible is really important and everyone can possibly contribute to the spread of this disease exactly. So, there was a nice retrospective analysis of this disease from patients in Wuhan, and in this analysis, the median age of people who were hospitalized with COVID was fifty six.

So although there are some good data that suggests that older ages are especially at risk for dying from COVID nineteen, this is by no means a disease only of older people, and it's not only older people who become severely ill from this virus.

Speaker 1

Number four, speaking of who gets super sick, we also talked with doctor Kraft about the case fatality rate. So I'm going to define that really quickly. The case fatality rate that you're probably hearing a lot about is the number of deaths divided by the total number of cases in a period of time. So that denominator, the total number of cases in a period of time, is determined by the number of people that we know are infected.

And as doctor Kraft said, in this case, if we're only testing the most severely symptomatic people, then that denominator is going to be small relative to the total number of people who might actually be infected. So then the numerator, the number on top the number of deaths, is going to be proportionally larger. So the bottom line is, we still don't know exactly how deadly this disease is, especially here in the US where we're only testing severely ill individuals.

For the most part, we do have some preliminary data in the US. This is from March sixteenth. This data, it suggests that mortality is definitely highest in people over eighty five, but in this group mortality ranges from ten to twenty seven percent, and in people between sixty five and eighty four, it ranged from three to eleven percent and it went down from there. But again, all this data is biased by the fact that we're only testing

the most severe cases. And as you've probably heard in the news, the case fatality rate thus far has been different in different countries, and that's likely because of both differences in ages of the population that gets ill in those countries, but also differences in their testing strategies as well.

Speaker 2

Mm hmm, yeah, which brings us to number five. Our last point, and that is that we do not have enough resources period period. We don't have enough resources, and that is super problematic, and it's no fault of the clinicians or the laboratorians who are now faced with having to decide who they can test with their limited supplies. And the thing is, if we don't stem this infection, that lack of supplies is only going to get worse.

And that's what we have seen in Italy. It's illustrated this perfectly because in some areas they don't have enough ventilators and they're having to decide who they're going to intubate and ventilate. That's a decision that no physician should ever have to make and We'll talk more in some of our future episodes about what has led to the

shortage and why we are facing it. But there's no doubt that it's making it harder to get this epidemic under control, and it's an enormous stressor on hospitals and healthcare workers.

Speaker 1

Yeah, it's pretty major. Okay, sources, sources, Aaron, we have a lot for this episode. So there was an article by lower at All. All of these are from twenty twenty. Okay, they're all written in the last month. There's an article from Lawer at All that was in Annals of Internal Medicine. From by at All in jama from Jao at All in the Lancet. We've got one from Wu and Magoogin in Jama Kong and Argowol in Radiology cardiothoracic Imaging. That one's great if you want some pictures of those ground

glass opacities. Le at All in Science. And then the CDC's MMWR report from March eighteenth is where I got those numbers on the age stratified deaths in the US so far.

Speaker 2

So we'll post all of those references on our website. This podcast will kill You dot Com so if you want to read up a little bit more, you know where to find them.

Speaker 1

Yep. Thank you again to doctor Colleen Kraft for taking the time out of your schedule to speak with us and to share what you have learned with our listeners. We really really appreciate it, we really do.

Speaker 2

And thanks to Bloodmobile for providing the music for this episode and all of our episodes.

Speaker 1

And thank you for sticking through chapter two. We'll see you next time chapter three.

Speaker 2

Until chapter three, wash your hands.

Speaker 3

You filthy animals.

Speaker 1

Ou

Transcript source: Provided by creator in RSS feed: download file
For the best experience, listen in Metacast app for iOS or Android